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Abstract
Background: Drug-related adverse events remain an important cause of morbidity and mortality and impose huge burden
on healthcare costs. Routinely collected electronic healthcare data give a good snapshot of how drugs are being used in
‘real-world’ settings.
Objective: To describe a strategy that identifies potentially drug-induced acute myocardial infarction (AMI) from a large
international healthcare data network.
Methods: Post-marketing safety surveillance was conducted in seven population-based healthcare databases in three
countries (Denmark, Italy, and the Netherlands) using anonymised demographic, clinical, and prescription/dispensing data
representing 21,171,291 individuals with 154,474,063 person-years of follow-up in the period 1996–2010. Primary care
physicians’ medical records and administrative claims containing reimbursements for filled prescriptions, laboratory tests,
and hospitalisations were evaluated using a three-tier triage system of detection, filtering, and substantiation that
generated a list of drugs potentially associated with AMI. Outcome of interest was statistically significant increased risk of
AMI during drug exposure that has not been previously described in current literature and is biologically plausible.
Results: Overall, 163 drugs were identified to be associated with increased risk of AMI during preliminary screening. Of
these, 124 drugs were eliminated after adjustment for possible bias and confounding. With subsequent application of
criteria for novelty and biological plausibility, association with AMI remained for nine drugs (‘prime suspects’): azithromycin;
erythromycin; roxithromycin; metoclopramide; cisapride; domperidone; betamethasone; fluconazole; and megestrol
acetate.
Limitations: Although global health status, co-morbidities, and time-invariant factors were adjusted for, residual
confounding cannot be ruled out.
Conclusion: A strategy to identify potentially drug-induced AMI from electronic healthcare data has been proposed that
takes into account not only statistical association, but also public health relevance, novelty, and biological plausibility.
Although this strategy needs to be further evaluated using other healthcare data sources, the list of ‘prime suspects’ makes
a good starting point for further clinical, laboratory, and epidemiologic investigation.
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Introduction
Drug-related adverse events remain an important cause of
morbidity and mortality and impose a burden on healthcare costs.
[1,2,3] There is continuous influx of new drugs into the worldwide
market, but pre-approval clinical trials are unable to detect rare
adverse events and to provide a complete picture of a drug’s safety
profile, which evolves over its lifetime on the market. [4,5,6] Once
a drug is made available outside the limited study population of
clinical trials, there are bound to be changes in the circumstances
of the drug’s actual clinical use (including exposure of broader
population than was included in the clinical trials, off-label
indications, concomitant use with other drugs, and dosing regimen
changes) which may give rise to previously unobserved adverse
effects. Post-marketing surveillance has traditionally been carried
out by systematic manual review of spontaneous reports of adverse
drug reactions (ADRs). Enormous improvements in computing
capabilities have provided opportunities to partially automate
detection of potentially drug-induced adverse events and various
international initiatives are exploring new approaches to do this,
primarily through data mining of electronic healthcare records.
[7,8,9].
Electronic healthcare data, collected in the course of actual
clinical practice by physicians or of healthcare utilisation by
insurers and health maintenance organisations, give a good
snapshot of how drugs are being used in ‘real-world’ settings.
Being routine by-products of the healthcare delivery system, the
use of such data offers the advantage of efficiency in terms of time,
manpower, and financial costs needed to investigate patient safety
issues. While the advantages of automated surveillance are
obvious, there are growing concerns that such data mining may
generate more signals than can be followed up effectively with
currently available resources. This concern is not entirely
unfounded, considering that the annual volume of reports received
in spontaneous reporting systems (SRS), database systems primar-
ily designed for signal detection, has become enormous and
unmanageable. [10,11] The problem is likely to be worse with the
use of EHR data which have been intended for other purposes and
which can be mined for associations without routine human
evaluation of potential alternative explanations.
Detection of safety signals is only the initial step in the long and
complex process of post-marketing safety surveillance. The
evaluation of a signal may take years, from the earliest suspicion
of a potential risk to an established mechanism of causation and
fully understood phenomenon. [12] While signals derived from
EHR data may give a good snapshot of how drugs are being used
in real-world settings, there remains the need to establish
guidelines as to when - and how - to consider a safety signal
likely to be substantial enough to warrant verification and follow-
up. Various strategies for signal prioritisation have been proposed
in many publications, although most of these refer to signals
derived from SRS. [12,13,14,15,16] These strategies focus
consistently on signals with serious adverse effect, strong support-
ing evidence, and greatest public health impact.
In this paper we describe findings from post-marketing
surveillance using healthcare data of over 20 million individuals
from three European countries within the EU-ADR network
(http:\www.euadr-project.org). We look at primary care physi-
cians’ medical records which comprise detailed clinical informa-
tion including patients’ symptoms, physical examination findings,
diagnostic test results, and prescribed medications or other
interventions. We also look at administrative claims that document
reimbursements for filled prescriptions, laboratory and ancillary
tests, as well as hospitalisations. Taking the adverse event acute
myocardial infarction (AMI) as an example, we describe a strategy
for combining evidence from different data sources to identify
associations that may represent genuine risk and, hence,
necessitate further investigation through formal hypothesis testing
studies or action from drug regulatory agencies.
Methods
Data Sources
Identification of ‘prime suspects’ was performed in seven
databases of the EU-ADR network [8] for the period 1996–
2010: (1) Health Search/CSD LPD (HSD, Italy); (2) Interdisci-
plinary Processing of Clinical Information (IPCI, Netherlands); (3)
Pedianet (Italy); (4) PHARMO Network (PHARMO, Nether-
lands); (5) Aarhus University Hospital Database (Aarhus, Den-
mark); (6) Lombardy database (Lombardy, Italy); and (7) Tuscany
database (Tuscany, Italy). HSD, IPCI, and Pedianet are primary
care/general practitioner (GP) databases, where clinical informa-
tion and drug prescriptions are recorded. Aarhus, PHARMO,
Lombardy, and Tuscany are comprehensive record-linkage
systems where drug dispensing data are linked to registries
containing hospitalisation and other services. Table 1 provides
an overview of the characteristics of each database. All of the
databases in EU-ADR have been widely used for pharmacoepi-
demiologic research, have well-developed safeguard mechanisms
ensuring patient data protection, and have been validated for a
variety of drug exposures and clinical outcomes.
[17,18,19,20,21,22,23] Most healthcare services, including phar-
maceutical services, are provided for, or subsidised by, the state in
Italy and Denmark and covered by obligatory health insurance in
the Netherlands and turnover is low. In all of the countries with
GP databases, GPs function as ‘gatekeepers’ of the healthcare
system. A more detailed description of the database network can
be found in earlier publications. [8,24] Healthcare data used in
this study represent anonymised demographic and healthcare
information from 21,171,291 individuals with 154,474,063 per-
son-years of follow-up.
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Ethical Approval
The respective Scientific and Ethics committees of each
database approved the use of the data for this study. All of the
databases in the EU-ADR network adhere to local governance
rules regarding the storage of patient data and its use for research
and have well-developed safeguard mechanisms ensuring compli-
ance with the European directives and national regulations; no
individual written informed consent was required for this study.
Distributed Data Processing
A distributed database network approach was chosen in EU-
ADR, allowing database custodians to maintain local control of
their data, while reaching the goal of sharing data in a
standardised manner. Input data files are created locally and are
subsequently managed by purpose-built software called Jerboa,
written entirely in JavaTM to ensure that it will run in a wide
variety of computational environments. The software queries
patient-level data in the different databases, which are later
aggregated, de-identified and sent in encrypted format to a central
repository for evaluation and further analysis. This repository is
managed by the Department of Medical Informatics at Erasmus
Medical Center in the Netherlands, the project’s coordinating
centre.
Identification and Validation of Cases of Acute
Myocardial Infarction
Each of the databases in the EU-ADR network has unique
characteristics depending on its primary objective and local
function (i.e. administrative claims or medical records) and
contains medical information coded according to different
(natural) languages and disease terminologies. Potential cases of
AMI were identified using search queries that utilised three disease
coding terminologies: (1) International Classification of Primary
Care (ICPC) for IPCI; (2) International Classification of Diseases
9th revision-Clinical Modification (ICD-9CM) for ARS, HSD,
Lombardy, and PHARMO; and (3) ICD-10th revision for Aarhus.
To extract the same event across databases, these different
terminologies were mapped using the Unified Medical Language
System, a biomedical terminology integration system handling
more than 150 terminologies. The mapping ensured that AMI was
described using a common language. We identified AMI from the
databases using an iterative process that included harmonising
definitions based on clinical criteria established from literature,
using diagnosis codes and free text as well as laboratory findings
when available. We inspected differences in event ascertainment
by comparing data queries and benchmarking age-specific and
standardised incidence rates of the events (direct standardisation
was carried out using the WHOWorld Standard Population). The
incidence rates we obtained in EU-ADR are consistent with what
has been cited in previous literature. The multi-step process of
terminology mapping, harmonisation and benchmarking for the
data extraction for AMI (and for four other events) has been
described in more detail in earlier publications. [25,26] We
reproduce in Figure S1 (available as supplementary file online)
the schematic diagram summarising the harmonisation process of
event identification across the databases in EU-ADR.
Case validation by manual review of hospitalisation records and
GP records was done in a random subset of the cases. The overall
positive predictive value (PPV) for identifying AMI was good,
ranging from 75% (ICPC) to 95% (ICD9-CM) to 100% (ICD-10).
These findings are consistent with PPV estimates for ICD9-CM
and ICD-10 cited in the literature (To date there is no studyLe
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describing the PPV of ICPC codes or free text search for
identifying AMI). [27].
Only the first occurrence of AMI (i.e. incident case) was
considered in the analyses; patient time after an AMI was
censored.
Drug Exposure
Drug prescription/dispensing data were used to estimate event
rates during drug exposure and were assessed according to the
Anatomical Therapeutic Chemical (ATC) classification system of
the World Health Organization (WHO) (http://www.whocc.no/
atc/structure_and_principles/). The duration covered by each
prescription or dispensing was estimated according to legend
duration (if dosing regimen is available), or otherwise based on the
defined daily dose (http://www.whocc.no/ddd/definition_and_
general_considera/). Overlapping treatment episodes with the
same drug were combined into a single episode of drug use that
starts when the first prescription begins and stops when the last
prescription ends. When a patient uses more than one drug at a
time, the corresponding person-time is labelled accordingly.
Events are assigned to the episodes (drug use/non-use) in which
they occurred.
Screening for ‘Prime Suspects’
We developed a three-tier triage system (detection, filtering, and
substantiation) that generated a list of drugs potentially associated
with AMI (Figure 1).
Strength of statistical association. In the EU-ADR Project
we have applied a wide range of statistical methods, including
case-based methods (e.g., case control and self-controlled case
series), cohort methods, as well as methods developed initially for
use in spontaneous ADR reporting systems. We have previously
evaluated the relative performance of these methods for detecting
known ADRs from EHR data and our findings showed that
combinations of methods demonstrate good performance in
distinguishing known ADRs from negative controls. [28] Among
these methods, the Longitudinal Gamma Poisson Shrinker (LGPS,
an adaptation of the GPS, a data mining technique widely used in
spontaneous reporting systems to detect potential ADRs) [29] was
the best-performing among the methods. We calculated the
relative risk, RRLGPS and used this to rank the initial list of ‘prime
suspects.’ The results from the different databases were combined
to generate a single risk estimate per drug as if the databases
together form one large database. We did not perform any meta-
analyses. A value of RRLGPS$2.0 and a lower 95% CI of
RRLGPS.1 were used as threshold values for further processing. A
more detailed description of LGPS and how the RRLGPS is
calculated is given in Appendix S1 (available as supplementary
file online).
Alternative explanations for the identified associations:
protopathic bias and confounding. Another method, LEOP-
ARD (Longitudinal Evaluation of Observational Profiles of
Adverse events Related to Drugs), developed in EU-ADR,
attempts to single out associations that may be detected because
the drug is used to treat the event, or a prodrome of the event,
rather than cause it (protopathic bias). [29] For every suspect drug,
LEOPARD compares the rates of prescription starts within a fixed
window (625 days) before and after the event. An increase in the
number of prescriptions after an event relative to number of
prescriptions before the event is taken to be an indication of
protopathic bias. All drug-related AMI flagged by LEOPARD as
possibly due to protopathic bias were eliminated from the list. To
account for possible confounding, we further sorted out the list and
considered only associations that had significant increased risk
estimates based on the matched case-control method (lower 95%
CI of exposure odds ratio (OR).1) or the self-controlled case
series (SCCS) (lower 95% CI of incidence rate ratio
(IRRSCCS).1). In the case control method, each case was
matched to two controls of same age, sex, and index date (i.e.
date of AMI). To adjust for co-morbidity and global patient health
status, we used as proxy the number of different drugs an
individual was exposed to within the period one year and one
month prior to index date. We also employed the SCCS method
which controls for time-fixed confounders such as genetic factors,
Figure 1. Three-tier triage system (detection, filtering, and substantiation) for detecting ‘prime suspects’.
doi:10.1371/journal.pone.0072148.g001
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socio-economic status, individual frailty, and severity of underlying
disease.
Public health importance. To quantify the public health
impact of potentially drug-induced AMI, we used as surrogate the
number of excess cases of patients exposed to the drug relative to
the background unexposed population (observed – expected).
Automated Filtering and Substantiation of Signals
We have developed in the EU-ADR Project a web-based
platform that allows systematic analysis of potential safety signals
through several distributed software, streamlined into a single
computational workflow (https://bioinformatics.ua.pt/euadr).
The entry point of the system is a potential drug safety signal,
which is composed of a drug and its associated adverse event (in
this case AMI). Both signal filtering and substantiation are carried
out using dedicated bioinformatics methods integrated into
processing pipelines by means of Taverna, an open source
workflow management system used to design and execute scientific
workflows and aid in silico experimentation. We provide in Figure
S2 (available as supplementary file online) a schematic represen-
tation of the web platform set up. A more comprehensive
description of the EU-ADR web platform can be found in other
publications. [30,31].
Novel associations. The interest in drug safety surveillance
is discovery of phenomenon describing a ‘new potentially causal
association, or a new aspect of a known association.’ [32] To
discriminate among potentially relevant new and already known
associations, we used the abovementioned web platform to assess
previous reporting of such drugs with AMI in the biomedical
literature and eliminated from the list of ‘prime suspects’ drugs
previously reported to be associated with AMI in more than one of
three biomedical databases: MEDLINE (http://www.ncbi.nlm.
nih.gov/pubmed); DrugBank (http://www.drugbank.ca/); or
DailyMed (http://dailymed.nlm.nih.gov/dailymed/about.cfm).
The Medline ADR signal filtering workflow automates literature
analysis by assessing a list of publications regarding AMI. The
algorithm adopts a semantics-based approach that processes
Medline annotations looking for particular MeSH terms. This
workflow’s output is a direct relationship between AMI and its
descriptions in Medline, if present. In addition, there is a signal
filtering that identifies co-occurrence of the drug and the event (in
this case AMI) in Medline literature (Medline Co-occurrence) or
drug databases such as DailyMed (http://dailymed.nlm.nih.gov/)
or DrugBank (http://www.drugbank.ca/). The workflows use
statistical and text-mining techniques to evaluate drug names,
ATC codes and AMI co-occurrences in the indexed resources.
Substantiation for biological plausibility. As a final
assessment procedure, we retained in the ‘prime suspects’ list only
those associations for which a possible biologic mechanism could
be found. Automatic linkage of biomedical entities (drugs, proteins
and their genetic variants, biological pathways and clinical events)
via customised bioinformatics methods was done to find support-
Figure 2. Schematic representation of the process of substantiation of suspected drug-induced adverse events via proteins (A) and
via pathways (B). (From Bauer-Mehren A, van Mulligen EM, Avillach P, Carrascosa Mdel C, Garcia-Serna R, et al. (2012) Automatic filtering and
substantiation of drug safety signals. PLoS Comput Biol 8: e1002457. Reproduced with permission from the authors).
doi:10.1371/journal.pone.0072148.g002
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ing evidence for the ‘prime suspects’ (see Figure 2). The
associations that passed the screening described above were
processed by a computational framework that identifies pair-wise
relationships between the drug and AMI based on in silico
prediction of drug targets, analysis of drug metabolites and gene-
disease associations. [30].
Using the above substantiation requirement may preclude
finding drugs that induce AMI with mechanisms that cannot be
predicted from the drug’s pharmacological action. To account for
this type of ADRs, we determined which drugs would remain if we
keep those for which the substantiation workflow did not find
anything, but passed the novelty requirement. A manual literature
search was further performed to determine a logical explanation
for these associations.
Table 2. Drugs potentially associated with acute myocardial infarction{.
Therapeutic class Drug
RRLGPS
(95% CI)
OR
(95% CI)
IRRSCCS
(95% CI)
No. of
excess cases
Oral hypoglycemic agent Metformin and sulfonamides 2.5 (2.4, 2.6) 1.9 (1.8, 2.0) 1.5 (1.4, 1.6) 2,445
Antihypertensive Nifedipine 2.1 (2.0, 2.2) 1.6 (1.6, 1.7) 1.8 (1.7, 2.0) 2,097
Systemic corticosteroid Prednisone 2.5 (2.4, 2.6) 1.5 (1.4, 1.6) 2.2 (1.9, 2.6) 1,261
b-adrenergic agonist Salbutamol (systemic) 2.1 (2.0, 2.2) 1.2 (1.2, 1.3) 1.9 (1.6, 2.2) 1,017
Systemic corticosteroid Methylprednisolone 2.3 (2.2, 2.4) 1.5 (1.3, 1.6) 2.0 (1.7, 2.3) 832
Opioid analgesic Tramadol 2.1 (2.0, 2.2) 1.3 (1.2, 1.4) 2.2 (1.7, 2.8) 736
Oral hypoglycemic agent Glibenclamide 2.2 (2.1, 2.4) 1.6 (1.6, 1.8) 1.3 (1.1, 1.6) 686
Antihypertensive Clonidine 2.9 (2.7, 3.1) 1.8 (1.6, 1.9) 2.5 (1.9, 3.2) 650
Systemic antibiotic Clarithromycin 3.5 (3.2, 3.7) 2.4 (2.2, 2.6) 3.3 (2.8, 3.8) 645
b-adrenergic agonist Fenoterol (inhaled) 2.5 (2.3, 2.6) 1.4 (1.3, 1.5) 1.6 (1.1, 2.3) 588
b-adrenergic agonist Salbutamol (inhaled) 2.4 (2.2, 2.6) 1.3 (1.2, 1.4) 1.7 (1.4, 2.2) 510
Systemic antibiotic Amoxicillin 2.2 (2.0, 2.3) 1.6 (1.5, 1.8) 2.0 (1.8, 2.4) 497
Systemic corticosteroid Betamethasone 2.9 (2.7, 3.2) 1.7 (1.5, 2.0) 3.3 (2.6, 4.3) 365
Antacid Magaldrate 2.8 (2.5, 3.0) 1.9 (1.7, 2.2) 4.8 (3.9, 5.9) 365
Systemic antibiotic Phenoxymethylpenicillin 3.6 (3.3, 4.0) 2.6 (2.3, 2.9) 3.8 (3.0, 4.9) 335
Systemic corticosteroid Dexamethasone 3.2 (2.9, 3.5) 1.9 (1.7, 2.2) 5.4 (4.1, 7.2) 285
Antacid Combinations of aluminum,
magnesium, or calcium salts
3.1 (2.8, 3.5) 1.9 (1.6, 2.2) 4.4 (3.3, 5.7) 265
Opioid analgesic Fentanyl 2.5 (2.3, 2.8) 1.2 (1.1, 1.4) 2.1 (1.2, 3.9) 249
Antiemetic/gastric prokinetic Metoclopramide 5.7 (5.1, 6.4) 2.6 (2.2, 3.1) 8.9 (5.1, 15.6) 236
Antiemetic/gastric prokinetic Domperidone 2.8 (2.5,3.1) 1.6 (1.4, 1.8) 3.1 (2.4, 4.0) 229
Systemic antibiotic Azithromycin 2.8 (2.5, 3.2) 1.7 (1.5, 2.1) 2.5 (1.8, 3.5) 159
Systemic antibiotic Pivampicillin 4.5 (3.9, 5.2) 3.1 (2.6, 3.7) 3.6 (2.1, 6.1) 156
Systemic antibiotic Ceftriaxone 8.2 (7.0, 9.4) 5.2 (2.1, 13.1) 5.6 (2.8, 11.0) 154
Nonsteroidal
anti-inflammatory drug
Ketorolac 4.6 (3.9, 5.3) 2.7 (2.1, 3.4) 2.8 (1.7, 4.7) 135
Other anti-anemic Darbepoetin alfa 3.3 (2.8, 3.8) 1.7 (1.4, 2.1) 3.2 (1.8, 5.6) 126
Systemic antibiotic Cefixime 3.1 (2.6, 3.6) 2.4 (1.9, 3.1) 4.4 (3.1, 6.2) 104
Systemic antibiotic Roxithromycin 3.3 (2.8, 3.9) 2.4 (1.9, 3.0) 2.9 (1.8, 4.9) 89
Opioid analgesic Ketobemidone and antispasmodics 2.2 (1.9, 2.6) 1.2 (1.0, 1.5) 2.6 (1.2, 5.7) 78
Systemic antibiotic Dicloxacillin 2.6 (2.2, 3.1) 1.8 (1.5, 2.2) 2.5 (1.2, 5.2) 73
Antiemetic/gastric prokinetic Cisapride 2.1 (1.8, 2.5) 1.2 (1.0, 1.5) 2.4 (1.6, 3.6) 69
Antineoplastic/immunomodulator Azathioprine 2.1 (1.7, 2.4) 1.2 (1.1, 1.5) 3.4 (1.9, 6.1) 69
Oral hypoglycemic agent Gliquidone 2.7 (2.2, 3.2) 2.1 (1.6, 2.7) 2.2 (1.2, 4.0) 66
Systemic antibiotic Erythromycin 3.7 (3.0, 4.6) 2.6 (1.9, 3.4) 2.4 (1.1, 5.1) 63
Systemic antifungal Fluconazole 2.7 (2.2, 3.3) 1.5 (1.2, 2.0) 2.2 (1.2, 4.4) 53
Phosphate binder Polystyrene sulfonate 4.8 (3.6, 6.4) 2.2 (1.5, 3.1) 3.3 (1.1, 10.3) 48
Antiemetic/gastric prokinetic Butylscopolamine 5.8 (4.2, 7.7) 2.1 (1.4, 3.4) 11.3 (5.0, 25.8) 45
Antineoplastic/immunomodulator Megestrol 3.2 (2.5, 4.0) 2.5 (1.8, 3.4) 4.0 (1.8, 9.3) 44
Systemic antibiotic Ceftibuten 2.3 (1.8, 3.0) 1.9 (1.3, 2.7) 3.0 (1.7, 5.2) 31
Systemic antibiotic Rokitamycin 2.6 (1.8, 3.7) 1.8 (1.1, 3.0) 4.3 (2.3, 8.0) 18
doi:10.1371/journal.pone.0072148.t002
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Results
Identifying ‘Prime Suspects’
Overall, we found 235,283 cases of AMI (both drug-related and
non drug-related) during the period 1996–2010, with a back-
ground incidence rate of 153.7 per 100,000 person-years. We
initially identified 163 drugs possibly associated with AMI. We
subsequently flagged, and discarded from the list, 72 drugs as likely
being used to treat prodromal symptoms of AMI rather than cause
it (i.e. due to protopathic bias). Systemic antibiotics comprised
about one-fourth of the suspect drugs (22 drugs out of 91), with the
rest involving 14 other therapeutic classes. Adjustment for
confounding reduced the number of suspect drugs to 39. The
number of excess cases attributable to drug exposure ranged from
18 (for the antibiotic rokitamycin) to 2,445 (for metformin fixed-
dose combinations). Table 2 shows the list of suspect drugs that
passed preliminary screening, ranked according to a surrogate of
public health importance: the number of excess cases.
Filtering and Substantiation to Determine Novelty and
Plausibility of Associations
Out of the 39 drugs that passed initial screening, only 11 are
previously known from literature to be associated with AMI. After
applying criteria for both novelty and plausibility, we arrived at
nine ‘prime suspects’: the systemic macrolide antibiotics erythro-
mycin roxythromycin, and azithromycin; the gastric prokinetic
agents metoclopramide, cisapride, and domperidone; the antifun-
gal fluconazole; and the steroidal drugs betamethasone and
megestrol acetate (see Table 3).
Second Look at ‘Prime Suspects’: Idiosyncratic Reactions
Consideration of associations not substantiated by a known
biologic mechanism increased the number of ‘prime suspects’ to
27 (Table 3). Butylscopolamine is another prokinetic drug;
methylprednisolone is another corticosteroid; while pivampicillin,
phenoxymethylpenicillin, dicloxacillin, ceftriaxone, cefixime, cefti-
buten, and rokitamycin are all b-lactam antibiotics except for the
last one, which is a macrolide. Other drugs include the
bronchodilators fenoterol and salbutamol, antacids, the opioid
ketobemidone, and the phosphate binder polysterene sulfonate.
Discussion
We have described a strategy that identifies and prioritises
potentially drug-induced acute myocardial infarction from rou-
tinely collected healthcare data. We attempted to simulate how a
physician or drug regulator would go about evaluating suspected
drug-induced events. This is the first triage strategy for safety
surveillance developed for use – and tested – in data from
electronic healthcare records. In this strategy, we take into account
public health relevance, novelty, and biological plausibility in
addition to statistical association. Stepwise exclusion of alternative
causes is part of an etiology-based approach for the assessment of
ADRs. [33,34] While usually inherent in physician-reported
ADRs, such is not the case with associations obtained from
secondary healthcare data (particularly with insurance/adminis-
trative claims), which are inferred outside the actual physician-
patient encounter. We tried to offset this limitation by adjusting for
bias and confounding. The mechanisms behind most ADRs are
still not completely understood, but accumulating evidence over
the years indicate the interplay of various factors and increasing
role of inter-individual genetic variants in genes encoding drug-
metabolising enzymes and drug target genes. [35] The triage
strategy we developed takes into account various pathways that
can lead to a plausible explanation of the identified associations.
Because drugs belonging to the same class often have a similar
pharmacological mechanism of therapeutic action and adverse
effects, [36,37] we assumed that associations involving drugs of the
Table 3. ‘Prime suspects’: drugs potentially associated with increased risk of acute myocardial infarction which passed the filtering
(i.e. novelty) and substantiation (i.e. biological plausibility) criteria.
Drugs that satisfied both novelty and plausibility criteria Drugs that satisfied only novelty criterion
Metoclopramide Combinations of aluminum, magnesium, and calcium salts
Cisapride Magaldrate
Domperidone Butylscopolamine
Betamethasone Gliquidone
Erythromycin Metformin combinations with sulfonamides
Roxithromycin Methylprednisolone
Azithromycin Pivampicillin
Fluconazole Phenoxymethylpenicillin
Megestrol acetate Dicloxacillin
Ceftriaxone
Cefixime
Ceftibuten
Rokitamycin
Azathioprine
Ketobemidone and antispasmodics
Fenoterol (inhaled)
Salbutamol (inhaled)
Polystyrene sulfonate
doi:10.1371/journal.pone.0072148.t003
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same class may require more thorough investigation: systemic
antibiotics comprised about 25% of the initial list of suspect drugs.
The proposed mechanism underlying this association is via allergic
angina progressing to AMI. The occurrence of chest pain and
allergic-anaphylactic reaction, accompanied by clinical and
laboratory findings of classical angina pectoris, is caused by
inflammatory mediators released during an allergic insult and
constitutes the so-called Kounis syndrome. [38,39] Several studies
have shown that b-lactam antibiotics may cause allergic reactions
and initiate acute coronary syndrome in hypersensitive individuals.
Clinical manifestations of Kounis syndrome, including electrocar-
diographic findings, are similar to AMI. Kounis syndrome is
largely attributed to the action of cardiac mast cells found in the
coronary artery intimal layer and atherosclerotic plaques; it has
been demonstrated that the density of mast cells in the culprit
atheroma of patients who died from AMI was 200 times higher
than the density in normal coronary vessels from the same
patients. [40] These mast cells become activated during the
allergic reaction and release endogenous mediators, including
histamine, leukotrienes, thromboxane, platelet activation factor,
tryptase, chymase, and rennin - all of which affect different
receptors on the coronary vessel wall that may result in AMI. [41]
Histamine, the main amine released during allergic reactions,
plays a central role in the development of allergic AMI (see
Figure 3). The effects of histamine on cardiac function, including
increased cardiac contractility and heart rate as well as coronary
vasospasm, are mediated via H1- and H2- receptors situated on
the cardiac chambers and coronary arteries. In addition to direct
coronary vasoconstriction and thrombus generating effects,
histamine also potentiates the platelet aggregating response to
adrenaline. Kounis syndrome has previously been described with
use of penicillin, ampicillin, amoxicillin, cefuroxime, cefoperazone,
and cefoxitin. [41] To date, there have been no reports in the
literature associating macrolide antibiotics with the Kounis
syndrome. It is, possible, however, that macrolides induce
coronary vasopasm via the same mechanism as that of the b-
lactams. [42,43] Immediate-type hypersensitivity (i.e. anaphylaxis),
non-immediate reactions like fixed drug eruptions, toxic epidermal
necrolysis and leukocytoclastic vasculitis have been reported with
the use of macrolides. [42,44] Oral contraceptive use in women
and recreational drug use with cocaine are the main culprits
usually implicated when AMI occurs in a young patient with no
clinically evident coronary artery disease (CAD) or other known
cardiovascular risk factors. [45] With recent literature implicating
Kounis syndrome in drug-eluting stent thrombosis, [46] there is
good reason to believe that antibiotic-associated Kounis syndrome
is a condition that clinicians need to be more aware of. Although
the possibility of channeling bias in the association between
macrolides and AMI cannot be discounted (i.e. preferential use of
macrolide antibiotics in those patients who may be at higher risk
for developing hypersensitivity to b-lactams and, consequently, at
risk for developing Kounis syndrome), this association deserves
further investigation.
Among the gastric prokinetic drugs, cisapride has the most well
characterised cardiac adverse effect profile, which includes
ventricular arrhythmia, QT prolongation and torsades de pointes.
[47,48,49] Both metoclopramide and domperidone have also been
reported to have arrythmogenic potential. [50] The effects of these
drugs on the cardiovascular system are related to their action on
dopaminergic and 5-HT receptors; this could be the same
mechanism that predisposes to myocardial ischemia or infarction,
although how this may happen is yet unclear. [51].
Figure 3. Central role of histamine in drug-induced acute myocardial infarction via Kounis syndrome. Aside from its direct
vasoconstricting and thrombus-generating effects, histamine also potentiates the platelet aggregating response to adrenaline (dotted outline).
doi:10.1371/journal.pone.0072148.g003
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Long-term use of some drugs may increase risk for AMI by
accelerating development of atherosclerosis and CAD. Any drug
that alters the modifiable risk factors for CAD (e.g., cigarette
smoking, elevated plasma low-density lipoprotein cholesterol,
reduced plasma high-density lipoprotein cholesterol, hypertension,
obesity, and diabetes) [52] has the potential to increase the risk of
AMI. Lipodystrophy, weight gain, and hypertension are known
corticosteroid-induced adverse effects. [53] Hyperlipidemia is
usually associated with long-term corticosteroid use and cases of
AMI with use of systemic corticosteroids have also been
documented. [54] In a Danish study of patients with out-of-
hospital cardiac arrest, use of corticosteroids, bronchodilators, and
antipsychotics were found to have the strongest association up to
30 days before the event. [55] Moreover, corticosteroids are used
in patients with systemic lupus erythematosus (SLE), psoriasis, and
other rheumatologic diseases - accelerated atherosclerosis and
premature CAD are recognised complications of these disorders,
although the exact etiology remains unclear and is likely to be
multifactorial. [56,57] Megestrol acetate, a progesterone derivative
used for hot flushes and for palliative treatment of hormone-
dependent malignant neoplasms, may predispose to AMI via its
effects on known cardiovascular risk factors: weight gain,
hypertension, and hyperglycemia or diabetes mellitus occur with
use of megestrol via glucocorticoid action-mediated increased
peripheral insulin resistance, especially with long-term use.
[58,59,60] Fluconazole has been associated with cardiac adverse
effects including QT prolongation and torsades de pointes, [61,62]
but not with myocardial ischemia or infarction. Another drug
belonging to the same class, itraconazole, has been described as
causing a negative inotropic effect resulting in hypertension,
hypokalemia, and edema (congestive heart failure). [63,64] The
product label of itraconazole has been changed to include a
warning to avoid administration to patients with evidence, or
history, of heart failure (http://dailymed.nlm.nih.gov/dailymed/
lookup.cfm?setid = a4d555fa-787c-40fb-bb7d-b0d4f7318fd0).
Azole antifungals may trigger AMI in those already at risk by
modifying lipid profile, an important determinant of cardiovascu-
lar risk. The product label of fluconazole indicates that there have
been post-marketing reports of both hypercholesterolemia and
hypertriglyceridemia with fluconazole use (http://dailymed.nlm.
nih.gov/dailymed/lookup.cfm?setid = f694c617-3383-416c-91b6-
b94fda371204). Drug-drug interactions may also play a role in the
development of AMI, especially in high-risk patients who are
taking multiple cardiac drugs: all the azole antifungals inhibit
CYP450 enzymes to some degree and may predispose to adverse
cardiac complications, including rhythm problems and ischemia
or infarction. [65,66].
There are many recognised ADRs which cannot be predicted
from a drug’s pharmacological action and whose mechanisms
remain unclear and have yet to be elucidated. [67,68] We looked
at novel associations which were not obviously explained by the
drug’s pharmacology. Doing away with the substantiation
requirement, however, yielded drugs that are similar to those
already described.
Strengths and Limitations
We took into account global health status and co-morbidities,
but residual confounding cannot be ruled out. Dose-response
relationships, carryover effects, and effect of concomitant use of
other drugs (including drug-drug interactions) were not considered
in this triage strategy. Many new molecular entities are introduced
into the market every year and databases that catalog the
pharmacology and toxicology of these drugs (including informa-
tion on molecular targets and gene associations) need to be
continually updated. Furthermore, many of these bioinformatics
databases may not be publicly available and hence not easily
verifiable. Automated filtering and substantiation streamlined the
triage and greatly reduced manual work, but full automation is still
not possible at this time. Manual verification of the output
produced by these workflows, in terms of both accuracy and
completeness, remains a crucial step. Finally, safety surveillance
for ‘prime suspects’ in electronic healthcare data is, by definition, a
hypothesis-generating exercise. Formal clinical and epidemiologic
studies to investigate the associations identified by the triage
system as necessitating follow-up are obvious and necessary next
steps.
Conclusions
We have proposed a strategy to identify potentially drug-
induced acute myocardial infarction using electronic healthcare
records that takes into account not only statistical association, but
also public health relevance, novelty, and biological plausibility.
Although this strategy needs to be further evaluated using other
healthcare data sources, the list of ‘prime suspects’ makes a good
starting point for further clinical, laboratory, and epidemiologic
investigation.
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